Search  in | Advanced
   Print  

AABB Chagas' Biovigilance Network

The Chagas’ Disease Biovigilance Network records screening and confirmatory results from the testing of donors for antibodies to Trypanosoma cruzi, the agent of Chagas’ disease. Current data are being provided by those laboratories that are using the test licensed by FDA in January 2007 to screen blood donors for the T. cruzi antibody. These laboratories account for more than 65 percent of the total blood collected in the U.S.

This section includes maps showing the latest confirmed positive cases by ZIP code and a password-protected area for reporting of test results as well as more in-depth monitoring and assessment of Chagas’ activity.

Maps are updated weekly. For the most currently reported data, please use the reports, which access the active Chagas' Biovigilance Network database.


Chagas' Data Collection and Reports  (password-protected)


Continental U.S. Map: RIPA Positives (updated 7/24/08)

 

2084 repeat reactive donations were tested by the supplemental RIPA test for the antibody to T. cruzi, the agent for Chagas' disease. 570 of the repeat reactive donations were RIPA positive; 1456 were RIPA non-reactive, four were RIPA indeterminate. The remaining results are pending. Twenty testing laboratories reported data into the Chagas Network; twenty-two testing laboratories now access the Chagas Network for reporting purposes.

Continental U.S. Map: Repeat Reactive Donations (updated 7/24/08)

 

2129 donations were repeat reactive for the antibody to T. cruzi, the agent for Chagas' disease. 

Top


The data posted on this Web site is provided by third parties and is not verified by AABB.  Accordingly, AABB makes no guarantee or promise that the data is current, valid, or accurate. No content on this site is intended to constitute professional advice, whether medical, legal or otherwise. AABB expressly disclaims any liability or loss that may arise either directly or indirectly from relying on the information, services or other material on this site.

Reporting facilities that are HIPAA-compliant should determine what, if any, donor/patient information may be reported and should consider reporting only donors’ states of residence, not donor zip codes. AABB is not responsible for reporting facilities’ compliance with federal, state or local laws or regulations.

Top


Chagas' Data Collection and Reports 

Chagas' Data Collection  (password-protected)

Chagas' Data Reports  (password-protected)

Support

Chagas' Biovigilance Network Training Guide (PDF)

For technical support or for more information, call +1.800.793.9376 (weekdays between 8:30 am and 5:00 pm ET).

For optimal viewing, use Microsoft Internet Explorer® 6.0 or later and set your screen resolution to 1024 x 768.

Top

Last modified on 7/24/2008 10:09:21 AM
What's New!
Significant Changes to the Standards for Cellular Therapy Product Services, 3rd edition
Details
Proposed 6th edition of Standards for Immunohematology Reference Laboratories
Details
AABB Weekly Report - July 18, 2008
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
Billing and Reimbursement for Stem Cell Processing - Frequently Asked Questions and Answers
Details
Member Feedback Sought for AABB Online Forums
Details
Joint Statement Before ACBSA on the Clinical Significance of Red Cell Age in Transfusions
Details
Announcement of Nominees for the AABB Board of Directors
Details
2008 West Nile Virus Biovigilance Network
Details
Association Bulletin #08-03 - West Nile Virus – Revised Recommendations for Triggering Individual Donation Nucleic Acid Testing and Use of Communication Plans
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details
Instructions on Applying for an AABB Variance
Details